Reed Tuckson's Insider Trades & SAST Disclosures
Reed Tuckson's most recent trade in Henry Schein Inc. was a trade of 2,844 Common Stock, par value $0.01 per share done . Disclosure was reported to the exchange on March 4, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Reed Tuckson.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Henry Schein Inc. | Reed V. Tuckson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 2,844 | 10,430 (0%) | 0% | 0 | Common Stock, par value $0.01 per share | |
| Henry Schein Inc. | Reed V. Tuckson | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 70.31 per share. | 04 Mar 2025 | 572 | 7,586 (0%) | 0% | 70.3 | 40,217 | Common Stock, par value $0.01 per share |
| Adverum Biotechnologies Inc | Reed V. Tuckson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 10,520 | 10,520 | - | - | Stock Option (Right to Buy) | |
| Henry Schein Inc. | Reed V. Tuckson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 2,604 | 8,158 (0%) | 0% | 0 | Common Stock, par value $0.01 per share | |
| Henry Schein Inc. | Reed V. Tuckson | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 76.88 per share. | 01 Mar 2024 | 495 | 5,554 (0%) | 0% | 76.9 | 38,056 | Common Stock, par value $0.01 per share |
| Adverum Biotechnologies Inc | Reed Tuckson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Henry Schein Inc. | Reed Tuckson | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 78.15 per share. | 16 Mar 2023 | 446 | 6,049 (0%) | 0% | 78.2 | 34,855 | Common Stock, par value $0.01 per share |
| Henry Schein Inc. | Reed Tuckson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 2,250 | 6,495 (0%) | 0% | 0 | Common Stock, par value $0.01 per share | |
| Adverum Biotechnologies Inc | Reed Tuckson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Adverum Biotechnologies Inc | Reed Tuckson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2021 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges